covid-19 testing pandemic vaccine

GSK partners with Medicago to develop plant-based Covid-19 vaccine

Reading now: 389
www.pharmaceutical-technology.com

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.GlaxoSmithKline (GSK) has partnered with Canadian biopharmaceutical firm Medicago to develop, assess and manufacture a plant-based adjuvanted Covid-19 vaccine candidate.

As part of the collaboration, GSK’s pandemic adjuvant system will be combined with Medicago’s recombinant Coronavirus Virus-Like Particles (CoVLP), which mimic the novel coronavirus’ structure and enable identification by the immune system.

An adjuvant is intended to enhance the immune response and minimise the amount of antigen required per dose, facilitating the production of more vaccine doses.

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA